Cargando…

Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression

Only scarce data on liver steatosis in children with chronic hepatitis B and C (CHB and CHC) are available. The objective of this study was to evaluate the prevalence, predictors, and impact of hepatic steatosis on children with CHB and CHC. A total of 78 patients aged 11.5 ± 3.4 years were included...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokorska-Śpiewak, Maria, Kowalik-Mikołajewska, Barbara, Aniszewska, Małgorzata, Pluta, Magdalena, Walewska-Zielecka, Bożena, Marczyńska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279083/
https://www.ncbi.nlm.nih.gov/pubmed/28099338
http://dx.doi.org/10.1097/MD.0000000000005832
_version_ 1782502712192008192
author Pokorska-Śpiewak, Maria
Kowalik-Mikołajewska, Barbara
Aniszewska, Małgorzata
Pluta, Magdalena
Walewska-Zielecka, Bożena
Marczyńska, Magdalena
author_facet Pokorska-Śpiewak, Maria
Kowalik-Mikołajewska, Barbara
Aniszewska, Małgorzata
Pluta, Magdalena
Walewska-Zielecka, Bożena
Marczyńska, Magdalena
author_sort Pokorska-Śpiewak, Maria
collection PubMed
description Only scarce data on liver steatosis in children with chronic hepatitis B and C (CHB and CHC) are available. The objective of this study was to evaluate the prevalence, predictors, and impact of hepatic steatosis on children with CHB and CHC. A total of 78 patients aged 11.5 ± 3.4 years were included: 30 (38%) had CHB, and 48 (62%) had CHC. Steatosis was scored on a 5-point scale, as follows: absent; minimal (≤5% hepatocytes affected), mild (6–33%), moderate (34–66%), and severe (>66%). Stepwise logistic regression was used to determine the factors associated with steatosis and moderate-to-severe steatosis. Steatosis was observed in 4/30 (13%) patients with CHB and 13/48 (27%) patients with CHC (P = 0.17). Moderate-to-severe steatosis was observed in 6/78 (8%) patients: 1/30 (3%) had CHB and 5/48 (10%) had CHC (P = 0.40). The body mass index (BMI) z-score was positively associated with the presence of steatosis in children with CHB (odds ratio [OR] = 3.3, 95% confidence interval [CI]: 1.02–10.64). In CHC, steatosis occurred more frequently in patients with hepatitis C virus genotype 3 compared with other genotypes (P = 0.002). In patients with non-3 genotype hepatitis C virus, steatosis was associated with the stage of fibrosis (OR = 3.35, 95% CI: 1.01–11.07) and inversely associated with the duration of infection (OR = 0.74, 95% CI: 0.55–0.97). Moderate-to-severe steatosis was positively associated with the BMI z-score (OR = 3.62, 95% CI: 1.22–10.75) and stage of fibrosis (OR = 3.89, 95% CI: 1.05–14.47). Steatosis is a common finding in children with chronic viral hepatitis. It is associated with metabolic factors in CHB, whereas in patients with CHC, metabolic and viral factors may have a combined effect, leading to more advanced grades of steatosis in children with higher BMI z-scores. Moderate-to-severe steatosis is a predictor of advanced fibrosis in children with CHC.
format Online
Article
Text
id pubmed-5279083
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52790832017-02-08 Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression Pokorska-Śpiewak, Maria Kowalik-Mikołajewska, Barbara Aniszewska, Małgorzata Pluta, Magdalena Walewska-Zielecka, Bożena Marczyńska, Magdalena Medicine (Baltimore) 4900 Only scarce data on liver steatosis in children with chronic hepatitis B and C (CHB and CHC) are available. The objective of this study was to evaluate the prevalence, predictors, and impact of hepatic steatosis on children with CHB and CHC. A total of 78 patients aged 11.5 ± 3.4 years were included: 30 (38%) had CHB, and 48 (62%) had CHC. Steatosis was scored on a 5-point scale, as follows: absent; minimal (≤5% hepatocytes affected), mild (6–33%), moderate (34–66%), and severe (>66%). Stepwise logistic regression was used to determine the factors associated with steatosis and moderate-to-severe steatosis. Steatosis was observed in 4/30 (13%) patients with CHB and 13/48 (27%) patients with CHC (P = 0.17). Moderate-to-severe steatosis was observed in 6/78 (8%) patients: 1/30 (3%) had CHB and 5/48 (10%) had CHC (P = 0.40). The body mass index (BMI) z-score was positively associated with the presence of steatosis in children with CHB (odds ratio [OR] = 3.3, 95% confidence interval [CI]: 1.02–10.64). In CHC, steatosis occurred more frequently in patients with hepatitis C virus genotype 3 compared with other genotypes (P = 0.002). In patients with non-3 genotype hepatitis C virus, steatosis was associated with the stage of fibrosis (OR = 3.35, 95% CI: 1.01–11.07) and inversely associated with the duration of infection (OR = 0.74, 95% CI: 0.55–0.97). Moderate-to-severe steatosis was positively associated with the BMI z-score (OR = 3.62, 95% CI: 1.22–10.75) and stage of fibrosis (OR = 3.89, 95% CI: 1.05–14.47). Steatosis is a common finding in children with chronic viral hepatitis. It is associated with metabolic factors in CHB, whereas in patients with CHC, metabolic and viral factors may have a combined effect, leading to more advanced grades of steatosis in children with higher BMI z-scores. Moderate-to-severe steatosis is a predictor of advanced fibrosis in children with CHC. Wolters Kluwer Health 2017-01-20 /pmc/articles/PMC5279083/ /pubmed/28099338 http://dx.doi.org/10.1097/MD.0000000000005832 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4900
Pokorska-Śpiewak, Maria
Kowalik-Mikołajewska, Barbara
Aniszewska, Małgorzata
Pluta, Magdalena
Walewska-Zielecka, Bożena
Marczyńska, Magdalena
Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title_full Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title_fullStr Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title_full_unstemmed Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title_short Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression
title_sort liver steatosis in children with chronic hepatitis b and c: prevalence, predictors, and impact on disease progression
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279083/
https://www.ncbi.nlm.nih.gov/pubmed/28099338
http://dx.doi.org/10.1097/MD.0000000000005832
work_keys_str_mv AT pokorskaspiewakmaria liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression
AT kowalikmikołajewskabarbara liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression
AT aniszewskamałgorzata liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression
AT plutamagdalena liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression
AT walewskazieleckabozena liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression
AT marczynskamagdalena liversteatosisinchildrenwithchronichepatitisbandcprevalencepredictorsandimpactondiseaseprogression